Evaluation of the new INNOVANCE® PFA P2Y cartridge in patients with impaired primary haemostasis

References

• Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152–163
   PubMed Web of Science ®Google Scholar
• Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130: 3–10
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5(Suppl. 1)230–237
   PubMed Web of Science ®Google Scholar
• Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005; 51: 957–965
   PubMed Web of Science ®Google Scholar
• Koessler J, Kobsar AL, Rajkovic MS, Schafer A, Flierl U, Pfoertsch S, Bauersachs J, Steigerwald U, Rechner AR, Walter U. The new INNOVANCE(R) PFA P2Y cartridge is sensitive to the detection of the P2Y receptor inhibition. Platelets 2011; 22: 19–25
   Web of Science ®Google Scholar
• Edwards A, Jakubowski JA, Rechner AR, Sugidachi A, Harrison P, Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y(12) blockade and influence of anticoagulant. Platelets 2011. Epub ahead of print
   Google Scholar
• Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev 2007; 21: 89–97
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103–2114
   PubMed Web of Science ®Google Scholar
• Koessler J, Witz E, Plass A, Sommer C, Steigerwald U, Walter U, Heterich S. Von Willebrand disease caused by compound heterozygosity for p.r854q and p.r760c: Diagnostic and therapeutic implications. Haemophilia 2011; 17: e240–e242
   Web of Science ®Google Scholar
• Tosetto A, Rodeghiero F, Castaman G, Bernardi M, Bertoncello K, Goodeve A, Federici AB, Batlle J, Meyer D, Mazurier C, et al. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 2007; 5: 715–721
   PubMed Web of Science ®Google Scholar
• Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 4: 774–782
   PubMed Web of Science ®Google Scholar
• Derhaschnig U, Schweeger-Exeli I, Marsik C, Cardona F, Minuz P, Jilma B. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia. Platelets 2010; 21: 320–328
   PubMed Web of Science ®Google Scholar
• Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000; 111: 1250–1252
   PubMed Web of Science ®Google Scholar
• Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand's disease: A critical review of the literature. J Thromb Thrombolysis 2006; 21: 175–178
   PubMed Web of Science ®Google Scholar
• Sadler JE. Low von Willebrand factor: Sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program 2009; 106–112
   PubMedGoogle Scholar
• Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 1998; 91: 1325–1331
   PubMed Web of Science ®Google Scholar
• Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: Comparison with the bleeding time. J Thromb Haemost 2007; 5: 2393–2398
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: Efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. Haemophilia. 2001; 7: 180–189
   PubMed Web of Science ®Google Scholar
• de Meijer A, Vollaard H, de Metz M, Verbruggen B, Thomas C, Novakova I. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin Pharmacol Ther 1999; 66: 425–430
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: A review of analytical variables, benefits and limitations. Haemophilia 2001; 7: 170–179
   PubMed Web of Science ®Google Scholar
• Skowasch D, Viktor A, Schneider-Schmitt M, Luderitz B, Nickenig G, Bauriedel G. Differential antiplatelet effects of angiotensin converting enzyme inhibitors: Comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril. Clin Res Cardiol 2006; 95: 212–216
   PubMed Web of Science ®Google Scholar
• Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89: 597–605
   PubMed Web of Science ®Google Scholar